A detailed history of Charles Schwab Investment Management Inc transactions in Myriad Genetics Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,083,302 shares of MYGN stock, worth $18.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,083,302
Previous 1,041,928 3.97%
Holding current value
$18.1 Million
Previous $25.5 Million 16.34%
% of portfolio
0.01%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$23.97 - $28.6 $991,734 - $1.18 Million
41,374 Added 3.97%
1,083,302 $29.6 Million
Q2 2024

Aug 12, 2024

BUY
$17.98 - $25.47 $997,206 - $1.41 Million
55,462 Added 5.62%
1,041,928 $25.5 Million
Q1 2024

May 08, 2024

BUY
$17.59 - $23.59 $1.06 Million - $1.42 Million
60,307 Added 6.51%
986,466 $21 Million
Q4 2023

Feb 06, 2024

BUY
$13.91 - $21.32 $575,220 - $881,645
41,353 Added 4.67%
926,159 $17.7 Million
Q3 2023

Nov 08, 2023

BUY
$15.99 - $23.22 $394,393 - $572,721
24,665 Added 2.87%
884,806 $14.2 Million
Q2 2023

Aug 09, 2023

SELL
$17.56 - $23.76 $185,732 - $251,309
-10,577 Reduced 1.21%
860,141 $19.9 Million
Q1 2023

May 11, 2023

BUY
$15.26 - $23.75 $459,081 - $714,495
30,084 Added 3.58%
870,718 $20.2 Million
Q4 2022

Feb 13, 2023

BUY
$14.51 - $20.99 $66,528 - $96,239
4,585 Added 0.55%
840,634 $12.2 Million
Q3 2022

Nov 14, 2022

BUY
$18.21 - $27.88 $389,348 - $596,102
21,381 Added 2.62%
836,049 $16 Million
Q2 2022

Aug 15, 2022

BUY
$16.45 - $25.88 $74,798 - $117,676
4,547 Added 0.56%
814,668 $14.8 Million
Q1 2022

May 13, 2022

BUY
$22.67 - $28.01 $394,231 - $487,093
17,390 Added 2.19%
810,121 $20.4 Million
Q4 2021

Feb 11, 2022

SELL
$24.13 - $32.63 $172,843 - $233,728
-7,163 Reduced 0.9%
792,731 $21.9 Million
Q3 2021

Nov 16, 2021

SELL
$29.97 - $36.66 $1.07 Million - $1.31 Million
-35,666 Reduced 4.27%
799,894 $25.8 Million
Q2 2021

Aug 16, 2021

BUY
$25.39 - $32.61 $382,931 - $491,824
15,082 Added 1.84%
835,560 $25.6 Million
Q1 2021

May 17, 2021

SELL
$19.92 - $31.6 $326,548 - $518,018
-16,393 Reduced 1.96%
820,478 $25 Million
Q4 2020

Feb 16, 2021

BUY
$12.16 - $19.77 $413,889 - $672,911
34,037 Added 4.24%
836,871 $16.6 Million
Q3 2020

Nov 13, 2020

BUY
$11.25 - $14.75 $43,076 - $56,477
3,829 Added 0.48%
802,834 $10.5 Million
Q2 2020

Aug 14, 2020

SELL
$10.69 - $16.49 $301,971 - $465,809
-28,248 Reduced 3.41%
799,005 $9.06 Million
Q1 2020

May 15, 2020

BUY
$9.78 - $29.53 $801,079 - $2.42 Million
81,910 Added 10.99%
827,253 $11.8 Million
Q4 2019

Feb 07, 2020

BUY
$20.93 - $35.1 $76,206 - $127,799
3,641 Added 0.49%
745,343 $20.3 Million
Q3 2019

Nov 08, 2019

SELL
$22.08 - $47.08 $893,047 - $1.9 Million
-40,446 Reduced 5.17%
741,702 $21.2 Million
Q2 2019

Aug 09, 2019

BUY
$22.67 - $35.0 $116,546 - $179,935
5,141 Added 0.66%
782,148 $21.7 Million
Q1 2019

May 14, 2019

SELL
$26.93 - $34.7 $511,589 - $659,195
-18,997 Reduced 2.39%
777,007 $25.8 Million
Q4 2018

Feb 14, 2019

BUY
$27.23 - $45.56 $323,846 - $541,845
11,893 Added 1.52%
796,004 $23.1 Million
Q3 2018

Nov 13, 2018

BUY
$37.57 - $50.34 $623,774 - $835,795
16,603 Added 2.16%
784,111 $36.1 Million
Q2 2018

Aug 08, 2018

BUY
$27.75 - $40.17 $3.01 Million - $4.35 Million
108,303 Added 16.43%
767,508 $28.7 Million
Q1 2018

May 07, 2018

SELL
$28.83 - $41.01 $43,936 - $62,499
-1,524 Reduced 0.23%
659,205 $19.5 Million
Q4 2017

Jan 17, 2018

BUY
$28.45 - $37.14 $847,724 - $1.11 Million
29,797 Added 4.72%
660,729 $22.7 Million
Q3 2017

Nov 13, 2017

BUY
$24.01 - $36.2 $15.1 Million - $22.8 Million
630,932
630,932 $22.8 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.35B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.